BioCentury | Nov 18, 2014
Company News

Actavis to acquire Allergan for $66B

...& Co. and BofA Merrill Lynch are Allergan's financial advisors and Latham & Watkins; Richards, Layton...
BioCentury | Jan 13, 2014
Company News

Endo, NuPathe, Teva deal

...disclose details. MTS Securities is a financial advisor to NuPathe, and Morgan Lewis and Richards, Layton...
BioCentury | Apr 19, 2004
Emerging Company Profile

Targacept: Life after nicotine

...is in Phase IIb testing for ADHD. Targacept in-licensed Inversine, which is not marketed, from Layton Bioscience Inc....
BioCentury | Oct 28, 2002
Company News

Sangamo management update

...Cardiovascular, Cancer, Neurological Hired: Janet Nibel as VP of finance and administration, formerly CSO of Layton BioScience Inc. WIR...
BioCentury | Sep 3, 2002
Company News

Layton, Targacept deal

...Targacept acquired Layton's Inversine mecamylamine nicotinic acetylcholine receptor antagonist, which is marketed to treat hypertension. Targacept...
...the University of South Florida that covers the use of mecamylamine to treat neuropsychiatric disorders. Layton...
...Syndrome. Targacept said it plans to reformulate Inversine and develop the product for CNS diseases. Layton Bioscience Inc....
BioCentury | Aug 27, 2002
Company News

Targacept acquires Layton's Inversine

...Targacept (Winston-Salem, N.C.) acquired Layton Bioscience's Inversine mecamylamine nicotinic acetylcholine receptor antagonist, which is marketed to...
...the University of South Florida that covers the use of mecamylamine to treat neuropsychiatric disorders. Layton...
BioCentury | Aug 27, 2001
Clinical News

LBS-neurons: Phase IIb

...although the researchers said the surrounding area in some patients maintained or even improved function. Layton BioScience Inc....
BioCentury | Aug 20, 2001
Finance

Private valuations falling

...pre-money, but it's much softer than a year ago." Gary Snable, CEO of neurological company Layton...
BioCentury | Aug 17, 2001
Financial News

Layton raises $8 million

...Neurological company Layton BioScience (Sunnyvale, Calif.) raised $8 million in a series F financing, through which...
BioCentury | May 14, 2001
Clinical News

LBS-neurons: Began Phase IIb trial

...Indication: Treat stroke End point: Neurologic status, stroke measures, functional disability, quality of life Status: Layton...
Items per page:
1 - 10 of 28
BioCentury | Nov 18, 2014
Company News

Actavis to acquire Allergan for $66B

...& Co. and BofA Merrill Lynch are Allergan's financial advisors and Latham & Watkins; Richards, Layton...
BioCentury | Jan 13, 2014
Company News

Endo, NuPathe, Teva deal

...disclose details. MTS Securities is a financial advisor to NuPathe, and Morgan Lewis and Richards, Layton...
BioCentury | Apr 19, 2004
Emerging Company Profile

Targacept: Life after nicotine

...is in Phase IIb testing for ADHD. Targacept in-licensed Inversine, which is not marketed, from Layton Bioscience Inc....
BioCentury | Oct 28, 2002
Company News

Sangamo management update

...Cardiovascular, Cancer, Neurological Hired: Janet Nibel as VP of finance and administration, formerly CSO of Layton BioScience Inc. WIR...
BioCentury | Sep 3, 2002
Company News

Layton, Targacept deal

...Targacept acquired Layton's Inversine mecamylamine nicotinic acetylcholine receptor antagonist, which is marketed to treat hypertension. Targacept...
...the University of South Florida that covers the use of mecamylamine to treat neuropsychiatric disorders. Layton...
...Syndrome. Targacept said it plans to reformulate Inversine and develop the product for CNS diseases. Layton Bioscience Inc....
BioCentury | Aug 27, 2002
Company News

Targacept acquires Layton's Inversine

...Targacept (Winston-Salem, N.C.) acquired Layton Bioscience's Inversine mecamylamine nicotinic acetylcholine receptor antagonist, which is marketed to...
...the University of South Florida that covers the use of mecamylamine to treat neuropsychiatric disorders. Layton...
BioCentury | Aug 27, 2001
Clinical News

LBS-neurons: Phase IIb

...although the researchers said the surrounding area in some patients maintained or even improved function. Layton BioScience Inc....
BioCentury | Aug 20, 2001
Finance

Private valuations falling

...pre-money, but it's much softer than a year ago." Gary Snable, CEO of neurological company Layton...
BioCentury | Aug 17, 2001
Financial News

Layton raises $8 million

...Neurological company Layton BioScience (Sunnyvale, Calif.) raised $8 million in a series F financing, through which...
BioCentury | May 14, 2001
Clinical News

LBS-neurons: Began Phase IIb trial

...Indication: Treat stroke End point: Neurologic status, stroke measures, functional disability, quality of life Status: Layton...
Items per page:
1 - 10 of 28